Shire launches ADHD tech challenge

Share this article:

Taking a page from Sanofi, Shire is preparing to launch a developer challenge “to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood.”

The company's two-stage Shire ADHD Transitions Challenge will shower $150,000 in awards on eight teams of developers. The overall winner will take home $100,000 and score two tickets to the Fall 2013 Health 2.0 conference, where their win will be announced.

Judges will be looking for tools that help ADHD patients manage transitions – such as those from high school to the less-structured environment of college life, or from college to the workforce – as well as addressing everyday organizational and life management challenges and encouraging medication adherence. For the first phase of the challenge (submissions are due by March 17), teams will submit a five-page plan. In the second phase, five finalist teams will execute on their plans.  

A 2007 survey suggests that almost 10% of US children and 4.4% of adults are affected by ADHD, for which Shire markets Adderall XR, Intuniv and Vyvanse.

Shire's contest is reminiscent of Sanofi's Data Design Diabetes and Collaborate | Activate challenges, for technology to help diabetes patients and patient advocacy groups, respectively.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...